275 related articles for article (PubMed ID: 30478448)
41. Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma.
Huq S; Casaos J; Serra R; Peters M; Xia Y; Ding AS; Ehresman J; Kedda JN; Morales M; Gorelick NL; Zhao T; Ishida W; Perdomo-Pantoja A; Cecia A; Ji C; Suk I; Sidransky D; Brait M; Brem H; Skuli N; Tyler B
Mol Cancer Ther; 2020 Sep; 19(9):1797-1808. PubMed ID: 32606016
[TBL] [Abstract][Full Text] [Related]
42. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.
Ilic N; Utermark T; Widlund HR; Roberts TM
Proc Natl Acad Sci U S A; 2011 Sep; 108(37):E699-708. PubMed ID: 21876152
[TBL] [Abstract][Full Text] [Related]
43. Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.
Volpon L; Osborne MJ; Zahreddine H; Romeo AA; Borden KL
Biochem Biophys Res Commun; 2013 May; 434(3):614-9. PubMed ID: 23583375
[TBL] [Abstract][Full Text] [Related]
44. Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells.
Thumma SC; Jacobson BA; Patel MR; Konicek BW; Franklin MJ; Jay-Dixon J; Sadiq A; De A; Graff JR; Kratzke RA
Cancer Gene Ther; 2015 Aug; 22(8):396-401. PubMed ID: 26227824
[TBL] [Abstract][Full Text] [Related]
45. Knockdown of eukaryotic translation initiation factor 4E suppresses cell growth and invasion, and induces apoptosis and cell cycle arrest in a human lung adenocarcinoma cell line.
Chen B; Zhang B; Xia L; Zhang J; Chen Y; Hu Q; Zhu C
Mol Med Rep; 2015 Dec; 12(6):7971-8. PubMed ID: 26498338
[TBL] [Abstract][Full Text] [Related]
46. Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis.
Pettersson F; Del Rincon SV; Emond A; Huor B; Ngan E; Ng J; Dobocan MC; Siegel PM; Miller WH
Cancer Res; 2015 Mar; 75(6):1102-12. PubMed ID: 25608710
[TBL] [Abstract][Full Text] [Related]
47. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G.
Moerke NJ; Aktas H; Chen H; Cantel S; Reibarkh MY; Fahmy A; Gross JD; Degterev A; Yuan J; Chorev M; Halperin JA; Wagner G
Cell; 2007 Jan; 128(2):257-67. PubMed ID: 17254965
[TBL] [Abstract][Full Text] [Related]
48. Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils.
Robichaud N; Hsu BE; Istomine R; Alvarez F; Blagih J; Ma EH; Morales SV; Dai DL; Li G; Souleimanova M; Guo Q; Del Rincon SV; Miller WH; Ramón Y Cajal S; Park M; Jones RG; Piccirillo CA; Siegel PM; Sonenberg N
Proc Natl Acad Sci U S A; 2018 Mar; 115(10):E2202-E2209. PubMed ID: 29463754
[TBL] [Abstract][Full Text] [Related]
49. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
Cope CL; Gilley R; Balmanno K; Sale MJ; Howarth KD; Hampson M; Smith PD; Guichard SM; Cook SJ
J Cell Sci; 2014 Feb; 127(Pt 4):788-800. PubMed ID: 24363449
[TBL] [Abstract][Full Text] [Related]
50. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.
Katsha A; Wang L; Arras J; Omar OM; Ecsedy J; Belkhiri A; El-Rifai W
Clin Cancer Res; 2017 Jul; 23(14):3756-3768. PubMed ID: 28073841
[No Abstract] [Full Text] [Related]
51. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling.
Soni A; Akcakanat A; Singh G; Luyimbazi D; Zheng Y; Kim D; Gonzalez-Angulo A; Meric-Bernstam F
Mol Cancer Ther; 2008 Jul; 7(7):1782-8. PubMed ID: 18644990
[TBL] [Abstract][Full Text] [Related]
52. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
Frolova O; Samudio I; Benito JM; Jacamo R; Kornblau SM; Markovic A; Schober W; Lu H; Qiu YH; Buglio D; McQueen T; Pierce S; Shpall E; Konoplev S; Thomas D; Kantarjian H; Lock R; Andreeff M; Konopleva M
Cancer Biol Ther; 2012 Aug; 13(10):858-70. PubMed ID: 22785211
[TBL] [Abstract][Full Text] [Related]
53. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
Lu H; Kojima K; Battula VL; Korchin B; Shi Y; Chen Y; Spong S; Thomas DA; Kantarjian H; Lock RB; Andreeff M; Konopleva M
Ann Hematol; 2014 Mar; 93(3):485-492. PubMed ID: 24154679
[TBL] [Abstract][Full Text] [Related]
54. Structure and functions of the translation initiation factor eIF4E and its role in cancer development and treatment.
Piserà A; Campo A; Campo S
J Genet Genomics; 2018 Jan; 45(1):13-24. PubMed ID: 29396141
[TBL] [Abstract][Full Text] [Related]
55. Differential network analysis and protein-protein interaction study reveals active protein modules in glucocorticoid resistance for infant acute lymphoblastic leukemia.
Mousavian Z; Nowzari-Dalini A; Rahmatallah Y; Masoudi-Nejad A
Mol Med; 2019 Aug; 25(1):36. PubMed ID: 31370801
[TBL] [Abstract][Full Text] [Related]
56. eIF4E is a central node of an RNA regulon that governs cellular proliferation.
Culjkovic B; Topisirovic I; Skrabanek L; Ruiz-Gutierrez M; Borden KL
J Cell Biol; 2006 Nov; 175(3):415-26. PubMed ID: 17074885
[TBL] [Abstract][Full Text] [Related]
57. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
58. Increased milk protein synthesis in response to exogenous growth hormone is associated with changes in mechanistic (mammalian) target of rapamycin (mTOR)C1-dependent and independent cell signaling.
Sciascia Q; Pacheco D; McCoard SA
J Dairy Sci; 2013 Apr; 96(4):2327-2338. PubMed ID: 23462168
[TBL] [Abstract][Full Text] [Related]
59. Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?
Borden KL; Culjkovic-Kraljacic B
Leuk Lymphoma; 2010 Oct; 51(10):1805-15. PubMed ID: 20629523
[TBL] [Abstract][Full Text] [Related]
60. Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.
Kosciuczuk EM; Saleiro D; Platanias LC
Cytokine; 2017 Jan; 89():116-121. PubMed ID: 27094611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
